Good Participatory Practice (GPP) for COVID-19 clinical trials: A toolbox

Overview

This document draws on the World Health Organization’s Good Participatory Practice Guidelines for Emerging Pathogens (GPP-EP) (2016) which were adapted in 2020 specifically for COVID-19. It will be updated as new resources are completed and approved.

Good Participatory Practice (GPP) can help ensure respectful community engagement and strengthen trust through collaborative partnerships.

The aims of this document are to:

• inform rapid engagement processes and activities with key stakeholders involved in implementing clinical research relevant to COVID-19
• provide user-friendly tools for rapid multi-stakeholder engagement